Building a Smarter Medical Devices Ecosystem in India: Regulatory Updates
Decision brief
Answer first · skim in under a minute
India's recent regulatory updates aim to streamline approvals, boost domestic manufacturing, and attract foreign investment in medical devices. This article outlines the changes, their implications for pharma business development, and answers key questions for investors and analysts.
Key questions this brief answers
- What specific changes have been introduced in the medical device regulations?
- How do these updates affect the approval timeline for combination products?
- What are the key opportunities for pharma-medtech partnerships in India?
Contents6 sections
Building a Smarter Medical Devices Ecosystem: India's New Rules
India's recent regulatory updates aim to streamline approvals, boost domestic manufacturing, and attract foreign investment in medical devices. This article outlines the changes, their implications for pharma business development, and answers key questions for investors and analysts.
Key Takeaways
- India's medical device exports crossed USD 4 billion in FY25, signaling strong market growth and global competitiveness, per a Press Information Bureau release.
- The National Medical Devices Policy 2023 provides the strategic framework for innovation and accessibility, now being operationalized through new regulatory measures announced in July 2025.
- India is poised to become a global hub for medtech manufacturing, as noted by Invest India, creating partnership opportunities for pharma companies developing combination products.
- Pharma BD teams should watch for clearer device classification and streamlined approval pathways that make India more attractive for co-development and in-market investments.
What regulatory changes are underway?
The foundation for the latest push is the National Medical Devices Policy 2023, which envisions placing the Indian medical devices sector "on an accelerated growth path with a patient-centric approach," according to the official strategy document. That document, published by the Department of Pharmaceuticals, outlined a broad agenda: promoting domestic manufacturing, improving quality infrastructure, and creating a conducive regulatory environment.
Now, policymakers are translating that vision into actionable rules. Export data from the government confirms that the sector has already hit a milestone — medical device exports crossed USD 4 billion in FY25. That surge gives New Delhi confidence that the sector can sustain growth if the regulatory framework is right. The new measures, reported by the Observer Research Foundation, focus on clearer device classification tiers, codified performance standards, and more robust post-market surveillance. For pharma companies that produce drug-device combinations — pre-filled syringes, inhalers, implantable pumps — the classification clarity alone could trim months from the approval timeline.
India is also aligning its risk-based categorization with international benchmarks, a move that simplifies global registration strategies for multinationals. The US FDA employs a similar three-tier risk classification (Class I, II, III) for medical devices, and aligning India's approach with such established frameworks reduces duplication for companies seeking simultaneous approvals in multiple markets. The Central Drugs Standard Control Organization is expected to release detailed implementation guidance in the coming quarters.
How should pharma business development teams respond?
For business development, regulatory affairs, and investment teams, the implications are concrete. India already accounts for a significant share of global generic drug production, but the medtech opportunity has been hampered by regulatory fragmentation. With export momentum exceeding USD 4 billion and a policy framework now in place, the country is widely seen as poised to become a global hub for medtech manufacturing, as the Invest India blog argues.
Pharma companies can now explore strategic partnerships with Indian device manufacturers to develop combination products or integrate digital health solutions into existing portfolios. Consider a drug-eluting stent or a connected autoinjector — these require both pharmaceutical and device expertise. The new regulatory clarity lowers the risk of such joint ventures. The push for local manufacturing may also incentivize companies to establish or expand production facilities in India, reducing costs and improving supply chain resilience. This aligns with the broader industry trend of diversifying manufacturing away from single-region dependencies.
Regulatory affairs teams should monitor the CDSCO's implementation details closely. Early engagement with Indian regulators could give first movers a head start in time-to-market for new combination products. The policy environment now favors companies that can move fast to structure co-development or licensing deals with Indian medtech players. The National Medical Devices Policy 2023 already envisions a "patient-centric approach" and "accelerated growth," and the upcoming rules will operationalize those goals.
Frequently Asked Questions
What specific changes have been introduced in the medical device regulations?
The government is operationalizing the National Medical Devices Policy 2023 through new rules that clarify device classification tiers, codify performance standards, and strengthen post-market surveillance. The Observer Research Foundation analysis notes that these changes aim to strike a balance between fostering innovation and ensuring safety. The exact timeline and compliance details are still being finalized by the Central Drugs Standard Control Organization, but the direction is toward a risk-based framework similar to those used in mature markets.
How do these updates affect the approval timeline for combination products?
Clearer device classification should reduce ambiguity for drug-device combination products, potentially shortening approval times. Pharma companies will no longer face as much uncertainty about whether a product falls under drug or device regulations. The new performance standards also provide predictable benchmarks for quality testing, which can speed up the review process once the framework is fully in force. The government's export data demonstrates that the sector is already scaling, and the regulatory updates are designed to sustain that momentum.
What are the key opportunities for pharma-medtech partnerships in India?
With export growth and regulatory stability, India becomes a more credible base for co-development of pre-filled syringes, drug-eluting implants, connected inhalers, and other combination products. Digital health integrations — where software-as-a-medical-device complements a pharmaceutical therapy — also look more viable. Business development teams should watch for joint ventures and licensing deals that leverage India's manufacturing cost advantages and fast-growing domestic demand. Invest India, the national investment promotion agency, highlighted the country's competitive manufacturing costs, skilled workforce, and large patient population as key drivers of the medtech opportunity.
Related coverage
Regulatory catalyst tracker
Track upcoming PDUFA dates and regulatory milestones for drugs in this story.
Unlock full calendar →Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
